- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03664388
Registry of Acute Coronary Syndrome From University Hospital of Vigo (CardioCHUVI)
Registry of Patients Admitted by Acute Coronary Syndrome to University Hospital of Vigo
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
CardioCHUVI is a retrospective study aim to analyze all consecutively patients admitted by acute coronary syndrome to University Hospital Alvaro Cunqueiro of Vigo, between January 2010 to January 2018
The objective of the project was to study cardiac and bleeding complications, such as reinfarction, heart failure, atrial fibrillation, stroke, and bleeding events, together with all-cause and cardiac mortality
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Sergio Raposeiras Roubín, MD, PhD
- Phone Number: 0034 620170387
- Email: raposeiras26@hotmail.com
Study Contact Backup
- Name: Emad Abu Assi, MD, PhD
- Email: eabuassi@gmail.com
Study Locations
-
-
Pontevedra
-
Vigo, Pontevedra, Spain, 36312
- Recruiting
- Department of Cardiology, Hospital Álvaro Cunqueiro
-
Contact:
- ANDRES IÑIGUEZ ROMO, MD, PhD
- Email: andres.iniguez.romo@sergas.es
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Any patient admitted to University Hospital Alvaro Cunqueiro of Vigo for acute coronary syndrome.
Exclusion Criteria:
- Secondary acute coronary syndromes during a hospital admission for another cause (i.e. acute myocardial infarction in the context of a sepsis)
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All cause mortality
Time Frame: Through study completion, an average of 3 years
|
Death for any cause
|
Through study completion, an average of 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reinfarction
Time Frame: Through study completion, an average of 3 years
|
New spontaneous acute myocardial infarction
|
Through study completion, an average of 3 years
|
Bleeding
Time Frame: Through study completion, an average of 3 years
|
Any bleeding according to BARC definition (from 1 to 5)
|
Through study completion, an average of 3 years
|
Ischemic stroke
Time Frame: Through study completion, an average of 3 years
|
Ischemic stroke documented in CT
|
Through study completion, an average of 3 years
|
Cancer
Time Frame: Through study completion, an average of 3 years
|
Any type of malignant cancer
|
Through study completion, an average of 3 years
|
Heart Failure
Time Frame: Through study completion, an average of 3 years
|
Heart Failure admissions
|
Through study completion, an average of 3 years
|
Atrial Fibrillation
Time Frame: Through study completion, an average of 3 years
|
Atrial fibrillation documented in ECG
|
Through study completion, an average of 3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Emad Abu-Assi, MD, PhD, University Hospital Alvaro Cunqueiro, Vigo, Spain
- Principal Investigator: Sergio Raposeiras-Roubín, MD, PhD, University Hospital Alvaro Cunqueiro, Vigo, Spain
- Study Director: Andres Iñiguez-Romo, MD, PhD, University Hospital Alvaro Cunqueiro, Vigo, Spain
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Disease
- Syndrome
- Acute Coronary Syndrome
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Platelet Aggregation Inhibitors
- Purinergic P2Y Receptor Antagonists
- Purinergic P2 Receptor Antagonists
- Purinergic Antagonists
- Purinergic Agents
- Ticagrelor
- Clopidogrel
Other Study ID Numbers
- Hospital Alvaro Cunqueiro
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Coronary Syndrome
-
Yonsei UniversityRecruitingCoronary Artery Disease, Acute Coronary SyndromeKorea, Republic of
-
Meditrix CorpNational University of Ireland, Galway, Ireland; Boston Scientific Japan K.K.; Fujita Health UniversityRecruitingChronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromeJapan, Ireland
-
OrbusNeichDuke Clinical Research Institute; OrbusNeich Medical K.K.CompletedCoronary Arteriosclerosis | Non ST Segment Elevation Acute Coronary SyndromeUnited States, Japan
-
Medical University of WarsawRecruitingAcute Coronary Syndrome | Chronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromePoland
-
Niguarda HospitalCompletedAcute Coronary Syndrome With ST Elevation on Electrocardiogram | Acute Coronary Syndrome Without ST Elevation on Electrocardiogram | Noncritical Coronary Artery Disease Coronary Stenosis Less Than 50 Per Cent | Aortic AneurysmsItaly
-
Sohag UniversityRecruitingLeft Main Coronary Artery Disease With Acute Coronary SyndromeEgypt
-
Eli Lilly and CompanyDaiichi Sankyo, Inc.CompletedCoronary Arteriosclerosis | Acute Coronary SyndromesUnited States
-
University of PatrasCompletedCoronary Artery Disease (CAD) | Acute Coronary Syndrome (ACS)Greece
-
The First Affiliated Hospital with Nanjing Medical...Unknown
-
Yonsei UniversityCompletedAcute Coronary Syndrome (ACS)Korea, Republic of
Clinical Trials on Dual antiplatelet therapy with ticagrelor/prasuglre
-
Institute of Cardiology, Warsaw, PolandMedical Research Agency, PolandRecruitingAtrial FibrillationPoland
-
National Institute of Cardiology, Warsaw, PolandMedical Research Agency, PolandRecruitingAtrial FibrillationPoland
-
Seoul National University HospitalLudwig-Maximilians - University of Munich; ST. Antonius hospital NieuwegeinRecruitingCoronary Artery Disease | Acute Coronary SyndromeKorea, Republic of
-
Seoul St. Mary's HospitalAstraZeneca; The Catholic University of Korea; Chonnam National UniversityUnknownBleeding | Percutaneous Coronary Intervention | Acute Myocardial Infarction | Major Adverse Cardiovascular EventsKorea, Republic of
-
Yonsei UniversityNot yet recruiting
-
China National Center for Cardiovascular DiseasesRecruitingMyocardial Infarction | Myocardial Ischemia | Coronary Artery Disease | Bleeding | Angina Pectoris | Dual Antiplatelet Therapy | Coronary Artery Bypass GraftingChina
-
The First Affiliated Hospital with Nanjing Medical...RecruitingIntracranial Aneurysm | Stent ComplicationChina
-
University Hospital of FerraraCompletedMyocardial Ischemia | Quality of Life | Hemorrhage | Platelet Aggregation InhibitorsItaly
-
Alejandro Gonzalez-OjedaCompletedPostoperative Infection | Lymphocele | Urological System Complication of Procedure | Vascular Postoperative ComplicationsMexico
-
HonorHealth Research InstituteBoston Scientific CorporationActive, not recruitingCoronary Artery Disease | Atherosclerosis | Stent PlacementUnited States